PBS support for Far North Queenslanders living with leukaemia
Patients living with one of Australia’s most common forms of leukaemia are set to benefit from expanded access to a breakthrough medicine through the Pharmaceutical Benefits Scheme. From 1 December, access to Venclexta® will be extended in combination with obinutuzumab for the first-line treatment of patients with chronic lymphocytic leukaemia who have co-existing conditions and…